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Abstract
Many efforts to reduce prostate specific antigen (PSA) overdiagnosis and overtreatment have been made. To this aim,
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) have been proposed as new more specific biomarkers. We
evaluated the ability of phi and PCA3 to identify prostate cancer (PCa) at initial prostate biopsy in men with total PSA range
of 2–10 ng/ml. The performance of phi and PCA3 were evaluated in 300 patients undergoing first prostate biopsy. ROC
curve analyses tested the accuracy (AUC) of phi and PCA3 in predicting PCa. Decision curve analyses (DCA) were used to
compare the clinical benefit of the two biomarkers. We found that the AUC value of phi (0.77) was comparable to those of
%p2PSA (0.76) and PCA3 (0.73) with no significant differences in pairwise comparison (%p2PSA vs phi p = 0.673, %p2PSA vs.
PCA3 p= 0.417 and phi vs. PCA3 p= 0.247). These three biomarkers significantly outperformed fPSA (AUC= 0.60), % fPSA
(AUC= 0.62) and p2PSA (AUC= 0.63). At DCA, phi and PCA3 exhibited a very close net benefit profile until the threshold
probability of 25%, then phi index showed higher net benefit than PCA3. Multivariable analysis showed that the addition of
phi and PCA3 to the base multivariable model (age, PSA, %fPSA, DRE, prostate volume) increased predictive accuracy,
whereas no model improved single biomarker performance. Finally we showed that subjects with active surveillance (AS)
compatible cancer had significantly lower phi and PCA3 values (p,0.001 and p= 0.01, respectively). In conclusion, both phi
and PCA3 comparably increase the accuracy in predicting the presence of PCa in total PSA range 2–10 ng/ml at initial
biopsy, outperforming currently used %fPSA.
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Introduction
The widespread use of PSA screening and extended prostate
biopsy protocols strongly increased the incidence of PCa and the
detection of low-risk tumors that may not clinically progress during
lifetime. However, preoperative tools (such as PSA and DRE) lack
accuracy to avoid many negative biopsies and to predict confined
PCa at radical prostatectomy (RP) [1].
Thus, several studies investigated the ability of new biomarkers
to improve PCa diagnosis reducing unnecessary biopsies and to
discriminate between aggressive and slow-growing cancers avoid-
ing overtreatment. Recently, Prostate cancer antigen 3 (PCA3)
and phi (prostate health index) have been proposed as useful tools
in prostate cancer patient care [2–8].
In 2012 PCA3 was approved by the US Food and Drug
Administration (FDA) for the use in men scheduled for repeat
biopsy and [22]proPSA for initial biopsy decisions in men with
PSA concentrations in the range of 4–10 ng/ml and negative
DRE.
Recently, Stephan et al [9] compared urinary PCA3, trans-
membrane protease, serine 2 (TMPRSS2):v-ets erythroblastosis
virus E26 oncogene homolog (avian) (ERG) gene fusion (T2:ERG),
and the serum phi for predicting biopsy outcome in a multicentre
study including men with PSA values between 0–20 ng/ml
undergoing first and repeat biopsy.
In addition, Scattoni et al [10] in a two centers study reported
that phi performed better than PCA3 as predictor of outcome both
in the initial and repeated biopsy.
Still, a direct comparison of phi and PCA3 in a single centre
study in subjects undergoing first biopsy with PSA values
comprised in the ‘‘grey’’ zone 2–10 ng/ml has not been available
until now.
Therefore, the aim of the present study was to compare the
diagnostic ability of PCA3 and phi in men who had undergone
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initial biopsies. Moreover, we stratified patient risk before
treatment, according to PRIAS criteria [11], thus we evaluated
not only the ability of the two biomarkers to detect PCa, but also
their correlation with active surveillance (AS) elegibility.
Materials and Methods
Study Population
Before prostate biopsy (minimum 16 cores), 332 subjects were
enrolled in a prospective observational study, approved by the
hospital ethics committee. Blood and urine specimens were
collected according to predetermined standard operating proce-
dure [12]. Participants provided written approved consent. Ethical
approval for this study was given by the institutional Ethics
Committee of the IRCCS Fondazione G. Pascale, Napoli, Italy
(M2/33).
Among these, 300 met eligibility criteria for this study: age over
50 years, no prior prostate surgery and biopsy, no bacterial acute
or chronic prostatitis, no use of 5-a reductase inhibitors, PSA
values included between 2 and 10 ng/ml, availability of serum
samples and corresponding clinical data and completion of at least
a 16 core template biopsy after enrollment. The final study cohort
included 108 PCa patients (36%) and 192 (64%) with no evidence
of malignancy (NEM).
Methods
Participants had blood drawn before DRE at each visit. Whole
blood was allowed to clot before serum was separated by
centrifugation. Serum aliquots were stored at 280uC until samples
were processed, according to Semjonow et al [13]. Specimens
were analyzed in blinded fashion for PSA, fPSA and p2PSA by
Access2 Immunoassay System analyzer (Beckman Coulter, Brea,
CA, USA) calibrated against the WHO standard for PSA and
fPSA. The analytical performance of the measurements assessed
with control materials (Beckman Coulter) showed values within the
allowed recommended limits.
After a DRE with 3 strokes per lobe as described earlier [14],
urine samples were collected (PROGENSA PCA3 urine sample
collection kit, Gen-Probe), and the PROGENSA PCA3 assay
(Gen-Probe, San Diego, CA, USA) was performed retrospectively
in all samples.
The PCA3 score was calculated as: (mRNA PCA3)/(mRNA
PSA) X 1000. Transrectal ultrasonography was used to determine
prostate volume.
Patients underwent prostate biopsies according to a standard-
ized institutional saturation scheme, which consisted of at least 16
needle biopsy cores obtained under transrectal-ultrasound (TRUS)
guidance. Primary and secondary Gleason score were assigned by
a single genitourinary pathologist blinded to the biomarkers
values, according to the 2005 consensus conference of the
International Society of Urological Pathology definitions [15].
Statistical Analysis
All statistical analysis were performed in R (R Development
Core Team, 2012).
Median [min–max] were used to describe continuous variables
while categorical variables were reported as number of occur-
rences and percentages. The Mann-Whytney and Chi-square test
were used to asses differences among PCa and NEM subjects. The
predictive accuracy of the single markers was measured by the
Area under the ROC curve (AUC). Differences in diagnostic
performance were assessed using the De Long method. Because of
the large number of the pairwise comparisons among markers and
to control the family-wise error rate at level a=0.05, the
significance of the DeLong test statistics was appraised by using
the adaptive Bonferroni procedure [16]. Sensitivities and specific-
ities at different cutoff (high sensitivity and best combination of
sensitivity and specificity) were compared using the Mc Nemar test
for paired proportions. Multivariable logistic regression analysis
was performed to assess whether addition of either PCA3 or phi
increased the predictive accuracy of a base set of predictors
routinely used as screening tool for the detection of prostate
cancer. Finally, Decision Curve analysis [17] was used to compare
the net benefit (calculated by subtracting the proportions of false
positive from the proportion of true positive, the former being
weighted by the relative harms of false positive and false negative
results) of using phi and PCA3 in guiding initial biopsy decision.
Statistical significance was set at p,0.05 (unless in AUC pairwise
comparisons as above stated).
Results
The demographic and clinical characteristics of the study
population (n= 300) are listed in Table 1.
The mean age (6 SD) of all the subjects included in this study
was 60.466.0 years. Positive biopsy for PCa was found in 108
(36%) patients. No significant differences were found between
patients with NEM and those with PCa for PSA, prostate volume
and PSA density, (p = 0.580, 0.413 and 0.266 respectively). Age
(p,0.001), fPSA (p 0.003), %fPSA (p 0.001), p2PSA (,0.001),
%p2PSA (,0.001), phi (,0.001), PCA3 (,0.001), percentage of
positive DRE (p,0.001) and positive family history (p = 0.01)
differed significantly between PCa and NEM patients.
Univariable Analysis
In table 2 and in figure 1, the results of ROC curve analysis for
all the markers are shown. The largest AUC’s were obtained with
phi (0.77; 95% C.I. 0.72 to 0.83), %p2PSA (0.76 with 95% C.I.
0.71 to 0.82) and PCA3 (0.73 with 95% C.I. 0.68 to 0.79) with no
significant differences in pairwise comparison (p = 0.673 compar-
ing %p2PSA vs phi, p = 0.417 comparing %p2PSA vs PCA3 and
p= 0.247 comparing phi vs PCA3). All of them outperformed
fPSA and %fPSA even after Bonferroni correction for multiple
comparisons (p,0.05 DeLong method; data not shown). Phi,
%p2PSA and PCA3 also showed comparable levels of specificity at
high level (90%) of sensitivity (p.0.05, Mac-Nemar test; data not
shown). When considering the cutoff achieving the best combina-
tion of sensitivity and specificity, both %p2PSA and phi showed a
significant improvement in sensitivity with respect to PCA3 (0.14,
95% C.I. [0.04 to 0.24], p = 0.01 and 0.19, 95% C.I. [0.08 to
0.30], p,0.01 respectively) without a significant difference in
specificity.
Multivariable Analysis
Both phi and PCA3 acted as independent predictors of PCa
when added to a base set of predictors including age, PSA, %
fPSA, EDR and prostate volume (Table 3). The diagnostic
accuracy of the base multivariable model was significantly
improved by the presence of phi (0.72, vs 0.82, p,0.001), PCA3
(0.72 vs 0.77 p= 0.015) and the combination of both markers
(0.72 vs 0.83 p,0.001). However, the multivariable models did
not improve the AUC over both phi and PCA3 as shown by
univariable analysis (p.0.05, De Long method, data not shown).
DCA Analysis
Results of the DCA analysis are reported in figure 2. Phi and
PCA3 exhibited a very close net benefit profile until the threshold
probability of 25% after that phi index had an increased net
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benefit against the PCA3 which endures for the defined range of
clinically plausible threshold probabilities (10–40%) [18]. For
example, at a threshold probability of 30%, the net benefit
associated to phi index and PCA3 were equal to 17.6% and
13.4%, respectively. This means that using phi index as diagnostic
tool led to a 21% reduction in the number of unnecessary biopsies
without increasing the proportion of PCa who properly underwent
to biopsy, compared to the reduction of 11% achieved by using
PCA3.
Univariable Analysis and Active Surveillance Predictors
In figure 3 we reported the results of univariable analysis testing
the ability of either phi or PCA3 in discriminating favorable from
unfavorable PCa according to PRIAS criteria (Biopsy Gleason
score #6, number of positive cores #2 and PSA density #20%,).
Individuals with prostate cancer compatible with AS had
significantly lower phi and PCA3 values than those who did not
match PRIAS criteria (p,0.001 and p= 0.01, respectively). Both
phi and PCA3 exhibited a significant different profile between
groups as regard Gleason score and number of positive cores,
whereas none of the two biomarkers were associated to PSA
density dichotomized at the value of 20%.
Discussion
It is generally accepted that PSA leaves much to be desired as
first-line diagnostic test and as predictive prognostic indicator. To
supplement the information from PSA analysis several biomarkers
have been proposed such as phi index and PCA3 score [2–7].
We recently reported [8] that PCA3 and phi perform
comparably in 160 men undergoing first prostate biopsy with
PSA values between 0 and 20 ng/ml. Accordingly, Stephan et al
[9] found that the ability to detect PCa of PCA3 and phi were not
significantly different in a multicentric cohort of 246 men
undergoing first and repeat biopsies with PSA values between 0
and 20 ng/ml. In the same report the authors showed that
although PCA3 had the largest AUC in the repeat biopsy cohort,
in the 2–10 ng/ml tPSA range group with negative DRE and in
the initial biopsy cohort the two biomarkers are similarly able to
detect PCa. On the other hand, univariable and multivariable
analysis performed by Scattoni et al [10] showed that phi was
slightly more accurate than PCA3 both in first and repeated biopsy
setting.
In this study we found that PCA3 and phi performed
comparably in a study population including 300 subjects
undergoing first biopsy with PSA values included in the ‘‘grey’’
zone 2–10 ng/ml. Differently from two previous studies [8,9], the
combination of the two biomarkers provided no additional
enhancement of the diagnostic power in our cohort. This result
may be explained on the basis of the study population selected by
different inclusion criteria particularly DRE, family history and
PSA values range used in the present study.
Multivariable analysis showed that the addition of phi and
PCA3 to a base model including currently used PCa predictors
Table 1. Clinical characteristics of study population.
PCa NEM Overall Population
(n=108) (n =192) (n=300) p
Age, media 65 58 60 ,0.001 {
(min-max), years (50–73) (50–70) (50–73)
tPSA, median 6.42 6.11 6.18 0.58 {
(min-max), ng/ml (2.11–10) (2.12–10) (2.11–10)
fPSA, median 0.87 1.09 0.97 0.003 {
(min-max), ng/ml (0–4) (0–4) (0–4)
p2PSA, median 20.08 16.08 17.04 ,0.001 {
(min-max),pg/ml (3.75–99.12) (3.54–102.82) (3.54–102.82)
phi, median 52.45 35.88 41.04 ,0.001 {
(min-max) (14.37–210.62) (14.02–109.92) (14.02–210.62)
PCA3, median 60 34 40 ,0.001 {
(min-max) (10–250) (2–257) (2–257)
%fPSA, median 0.17 0.19 0.19 0.001 {
(min-max) (0.03–0.60) (0.05–0.70) (0.03–0.7)
%p2PSA,median 2.31 1.5 1.76 ,0.001 {
(min-max) (0.51–10.84) (0.51–4.2) (0.51–10.84)
Prostate volume, 50 50 50 0.413 {
median(min-max),cc (20–90) (25–130) (20–130)
PSA density,median 0.12 0.11 0.11 0.266 {
(min-max) (0.05–0.26) (0.03–0.30) (0.030.30)
DRE positive, n (%) 36 (33) 22 (11) 58 (19) ,0.001 {{
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significantly increases predictive accuracy, according to Scattoni
et al [10]. However, the usefulness of multivariable models needs
to be further and extensively investigated, because no model
improved the performance of the single biomarker, as already
reported in our previous study [5].
Our findings open discussion about whether phi or PCA3 could
be recommended as the best single parameter in addition to PSA
‘‘grey’’ values as first line diagnostic test for PCa detection.
Recently [7,19], two different prospective multicenter studies
suggested that phi and %p2PSA provided significantly better
clinical performance than other PSA molecular forms assays in
detecting PCa in 2–10 ng/ml tPSA range. Hansen et al [20]
demonstrated that PCA3 achieved independent predictor status of
PCa in subjects undergoing first prostate biopsy. In studies
comparing phi and PCA3 performance in mixed biopsy patient
cohort [19], PCA3 score was more accurate than phi in the repeat
biopsy setting.
Both biomarkers are superior to the treat all strategy of
biopsying every patient only in a part (20–40%) of the defined
range of interest for prostate cancer threshold probability interval
[18]. Moreover, phi definitely surpasses PCA3 for threshold
probabilities above 25%.
Therefore, owing to its easier and cheaper technology, its lower
discomfort for the patients and its better ability to reduce
unnecessary biopsies (as shown by DCA), phi should be probably
recommended as the best assay in addition to PSA as first line
diagnostic test for PCa detection.
Taken together, literature data suggested that PCA3 could be
reserved for those patients undergoing repeat biopsies, for whom is
a well-established biomarker [2]. On the other hand, phi emerges
as a cheaper assay than PCA3, that hold promise to help urologist
to plan to take or not first biopsy, especially if future investigations
will further confirm phi test stability and reproducibility [7].
Moreover, in this study we firstly assessed the correlation of phi
and PCA3 with prognostic biopsy outcome such as Gleason sum
and positive core numbers and with PSA density. We found that
the two biomarkers significantly correlate with Gleason sum higher
than 6 and number of positive cores higher than 2 and inversely
with AS criteria compatibility. Previously published reports
investigated the value of phi or PCA3 to predict biopsy
Figure 1. Receiver operating characteristic (ROC) curve for comparing all the analyzed markers as predictor of PCa in first biopsy.
doi:10.1371/journal.pone.0067687.g001
Table 2. Results of the ROC curve analysis for all the studied
markers.
AUC (95% C.I.) 90% Sensitivity
Cut-off Specificities (95% C.I.)
tPSA 0.52 (0.45 to 0.59) 3.6 0.17 (0.07 to 0.24)
fPSA 0.60 (0.54 to 0.67) 0.6 0.15 (0.06 to 0.29)
%fPSA 0.62 (0.55 to 0.69) 0.1 0.20 (0.12 to 0.28)
p2PSA 0.63 (0.56 to 0.69) 9.5 0.18 (0.10 to 0.31)
%p2PSA 0.76 (0.71 to 0.82) 1.3 0.36 (0.17 to 0.52)
phi 0.77 (0.72 to 0.83) 31.6 0.40 (0.27 to 0.52)
PCA3 0.73 (0.68 to 0.79) 22.0 0.40 (0.28 to 0.48)
doi:10.1371/journal.pone.0067687.t002
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reclassification during AS[21–23] and pathological features at
radical prostatectomy [24,25]. Our encouraging results may help
to improve the selection of patients eligible for active surveillance
according to PRIAS criteria or for neurovascular bundle-sparing
surgery. Future multinstitutional studies on larger population are
needed to verify if combination of phi and PCA3 may improve
biopsy reclassification in subjects enrolled in an AS program.
Table 3. Predictive accuracy of the combined models in predicting the presence of PCa at initial biopsy.
Base Model Base Model+phi Base Model+PCA3 Base Model+phi+PCA3
Predictors of Pca O.R. (95% C.I.) p O.R. (95% C.I.) p O.R. (95% C.I.) p O.R. (95% C.I.) p
Age 1.10 (1.05 to 1.14) ,0.001 1.09 (1.04 to 1.14) ,0.001 1.08 (1.03 to 1.13) ,0.001 1.08 (1.03 to 1.14) ,0.001
PSA 0.97 (0.85 to 1.09) 0.575 0.84 (0.73 to 0.98) 0.023 0.94 (0.83 to 1.08) 0.382 0.85 (0.73 to 0.98) 0.027
% fPSA 0.02 (0.00 to 0.59) 0.024 0.08 (0.00 to 2.80) 0.167 0.04 (0.00 to 1.32) 0.071 0.10 (0.00 to 3.42) 0.198
DRE (positive vs negative) 3.47 (1.82 to 6.58) ,0.001 2.57 (1.26 to 5.24) 0.010 2.89 (1.48 to 5.67) 0.002 2.37 (1.14 to 4.93) 0.021
Prostate volume 0.99 (0.97 to 1.01) 0.215 0.99 (0.97 to 1.01) 0.507 0.99 (0.97 to 1.01) 0.279 0.99 (0.97 to 1.02) 0.547
phi – – 1.05 (1.03 to 1.07) ,0.001 – – 1.05 (1.03 to 1.07) ,0.001
PCA3 – – – – 1.02 (1.01 to 1.02) ,0.001 1.01 (1.00 to 1.02) 0.016
AUC (95% C.I.) 0.72 (0.67 to 0.79) 0.82 (0.77 to 0.87) 0.77 (0.72 to 0.83) 0.83 (0.78 to 0.87)
pu – ,0.001 0.025 ,0.001
uCompared with the base model - De Long method.
doi:10.1371/journal.pone.0067687.t003
Figure 2. Decision curve analysis. The net benefit (calculated by subtracting the proportions of false positive from the proportion of true positive,
the former being weighted by the relative harms of false positive and false negative results) of both phi and PCA3 is plotted against the threshold
probability (the probability of PCa at which the benefits of opting for biopsy or no biopsy are considered equal). Solid lines represent the net benefit
associated to the benchmarking strategies of biopsying all or no men irrespective of any diagnostic tool.
doi:10.1371/journal.pone.0067687.g002
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Figure 3. PCA3 and phi ability in discriminating PCa according to PRIAS criteria. Box plot shows the distribution of PCA3 values (upper
panel) and phi values (lower panel) in patients with biopsy proven PCa classified according to the PRIAS criteria for active surveillance. Data are
shown as median (horizontal line in the box) and Q1 and Q3 (borders of the box). Whiskers represent the lowest and the highest values that are not
outliers (i.e., data points below Q1–1.5x IQR or above Q3+1.5x IQR) or extreme values (i.e., data points below Q1–3xIQR or above Q3+3xIQR). Dots
represent outlier values and asterisks represent extreme values. Q1= 25th percentile; Q3= 75th percentile; IQR (interquartile range) =Q3–Q1.
doi:10.1371/journal.pone.0067687.g003
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The strengthen of our study resides in a single centre dataset
including subjects at first biopsy allowing us to assess the net
clinical benefit of one marker over the other and to define cut-offs
calculated on a large population. Unfortunately, PCa patients
number is not enough to evaluate the ability of phi and PCA3
alone or in combination to predict clinically localized cancer
compatible with watchful waiting.
Conclusions
In patients with a tPSA between 2 and 10 ng/ml, phi and PCA3
are the strongest predictors of PCa and are significantly more
accurate than the currently used tests in PCa detection. Moreover,
the two biomarkers are strongly correlated with biopsy outcomes,
suggesting a potential role in AS patients selection.
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